HENLIUS News

HENLIUS: VOLUNTARY ANNOUNCEMENT - 2024 FIRST QUARTERLY UPDATE

Apr 29 16:30

HENLIUS: INSIDE INFORMATION ANNOUNCEMENT - HLX02 (TRASTUZUMAB-STRF, PROPRIETARY NAME IN THE UNITED STATES: HERCESSI) FOR THE TREATMENT OF ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER AND METASTATIC GASTRIC CANCER APPROVED BY THE UNITED STATES FOOD AND DRUG ADMI

Apr 26 12:20

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST SUBJECT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY IN HEALTHY SUBJECTS OF HLX6018 IN MAINLAND CHINA

Apr 23 16:49

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE CLINICAL TRIAL OF HLX53 (ANTI-TIGIT FC FUSION PROTEIN) IN COMBINATION WITH HANSIZHUANG (SERPLULIMAB INJECTION) AND HANBEITAI (BEVACIZUMAB INJECTION) FOR THE FIRST-LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC

Apr 17 16:56

HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF DOMESTIC SHAREHOLDERS AND UNLISTED FOREIGN SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024

Apr 17 16:40

HENLIUS: FORM OF PROXY FOR THE 2024 FIRST CLASS MEETING OF H SHAREHOLDERS TO BE HELD ON MONDAY, 20 MAY 2024

Apr 17 16:39

HENLIUS: PROXY FORM FOR THE ANNUAL GENERAL MEETING TO BE HELD ON MONDAY, 20 MAY 2024 (OR ANY ADJOURNMENT THEREOF)

Apr 17 16:38

HENLIUS: 2023 Environmental, Social and Governance Report

Apr 17 16:33

HENLIUS: VOLUNTARY ANNOUNCEMENT - AN INTERNATIONAL MULTI-CENTRE PHASE 3 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK FO

Apr 5 18:00

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024

Apr 3 16:51

HENLIUS: PROPOSED CHANGE OF REGISTERED ADDRESS IN CHINA AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

Mar 21 17:00

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE FIRST PATIENT HAS BEEN DOSED IN A PHASE 1 CLINICAL STUDY OF HLX42 FOR INJECTION (ANTIBODY-DRUG CONJUGATE TARGETING EGFR WITH NOVEL DNA TOPOISOMERASE I INHIBITOR) FOR THE TREATMENT OF ADVANCE/METASTATIC SOLID TUMOURS IN

Mar 14 21:00

HENLIUS: VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL OF HLX6018 WAS APPROVED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Mar 12 18:20

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Mar 1 17:44

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE SUPPLEMENTAL APPLICATIONS OF HANDAYUAN (ADALIMUMAB INJECTION) FOR THE NEW INDICATIONS HAVE BEEN ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Feb 29 17:00

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Feb 6 16:41

HENLIUS: VOLUNTARY ANNOUNCEMENT - THE PHASE 1 CLINICAL STUDY OF A BIOSIMILAR OF DENOSUMAB HLX14 (RECOMBINANT ANTI-RANKL HUMAN MONOCLONAL ANTIBODY INJECTION) SUCCESSFULLY COMPLETED

Feb 1 16:50

HENLIUS: Notification Letter and Reply Form to Non-Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Jan 30 16:35

HENLIUS: Notification Letter and Reply Form to Registered Shareholders - Arrangement of Electronic Dissemination of Corporate Communications

Jan 30 16:30

HENLIUS: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

Jan 3 16:37